By this approach, we defined four different groups within cohort B: the HER2-positive group: n=20 (HER2-positive tumours); group 1: n=156 (HER2-negative, ER-positive tumours with intermediate ALCAM and low OPN expression); group 2: n=14 (HER2/ER-negative tumours with high OPN and low ALCAM expression); group 3: n=10 (HER2/ER-negative tumours with predominantly higher OPN and ALCAM expression). This evidence concerns the gene ERBB2 and neoplasm.